Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.

Adjusted annualized rate of change in T-scores for each Neuro-QoL domain Statistically significant improvements were seen in 8 of 12 Neuro-QoL domains in the overall natalizumab-treated population; the trend toward improvement in three other domains (emotional and behavioral dyscontrol, participation in social roles and activities, and upper extremity function) did not reach statistical significance ( Table 2 ).

also in 111,027 other papers